J
J. Murray
Researcher at Western General Hospital
Publications - 23
Citations - 578
J. Murray is an academic researcher from Western General Hospital. The author has contributed to research in topics: Letrozole & Anastrozole. The author has an hindex of 10, co-authored 20 publications receiving 551 citations.
Papers
More filters
Journal ArticleDOI
Letrozole Suppresses Plasma Estradiol and Estrone Sulphate More Completely Than Anastrozole in Postmenopausal Women With Breast Cancer
J Michael Dixon,Lorna Renshaw,O. Young,J. Murray,E. Jane Macaskill,M. McHugh,Elizabeth Folkerd,David Cameron,Roger A'Hern,Mitch Dowsett +9 more
TL;DR: Letrozole reduces plasma E2 and E1S levels to a significantly greater extent than anastrozoles in postmenopausal women taking AIs as part of their adjuvant therapy for hormone receptor-positive breast cancer.
Journal ArticleDOI
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.
William R. Miller,Alexey Larionov,Lorna Renshaw,Thomas J. Anderson,Sharon A. White,J. Murray,Emma L. Murray,Garret M. Hampton,John R. Walker,Steven Ho,Andreas Krause,Dean B. Evans,J M Dixon +12 more
TL;DR: Genes have been identified which either change markedly or consistently in breast cancer after 14 days treatment with letrozole, which are new important data in understanding letroZole's molecular mechanism of action in breast cancers.
Journal ArticleDOI
Increase in response rate by prolonged treatment with neoadjuvant letrozole
J Michael Dixon,Lorna Renshaw,E. Jane Macaskill,O. Young,J. Murray,David Cameron,Gillian R. Kerr,Dean B. Evans,William R. Miller +8 more
TL;DR: Continuing letrozole in responding patients beyond 3–4 months achieves further clinical reduction in tumour size and for elderly women with a short life expectancy letroZole alone may provide long-term disease control.
Journal ArticleDOI
Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole.
TL;DR: Letrozole produces rapid and profound decreases in expression of Ki67 and PgR but changes do not always correlate with clinical and pathological responses.
Journal ArticleDOI
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer
FM McCaig,Lorna Renshaw,Linda Williams,O. Young,J. Murray,Elizabeth J. Macaskill,M. McHugh,Rosemary A. Hannon,J Michael Dixon +8 more
TL;DR: Stopping tamoxifen therapy and starting AIs results in a significantly greater increase in bone turnover compared with commencing AIs in tamoxIFen-naïve patients, and AI-induced bone turnover increases over time.